Volume 50, Issue 8, August 2020

NCYM is an MYCN antisense gene that encodes de novo evolved protein and promotes tumor aggressiveness. Here, we review the current understanding of oncogenic functions and the clinical significance of NCYM.

The 8th edition TNM system for esophageal and esophagogastric junction (EGJ) cancer has been updated to include separate clinical, pathological and pathological prognostic stagings for EGJ and squamous cell carcinoma.

We examine the concordance between treatment recommendations for breast cancer by Watson for Oncology (WFO, artificial intelligence) and oncologists. WFO is a promising system for the treatment of breast cancer.

In this Phase 1 study, the safety/pharmacokinetic profile of tepotinib (a MET inhibitor) in Japanese patients with solid tumors supports further development at a dose of 500 mg/day orally.

Long-term epidural analgesia has definite analgesic effect for patients with terminal cancer. Adding cefazolin to local anesthetics has little systemic influence and few complications and can effectively prevent analgesic infection.

To examine factors affecting rates at which informed consent was obtained in randomized controlled trials for metastatic breast cancer patients, we conducted prospective studies with a self-administered questionnaire.

Four cycles of adjuvant chemotherapy can reduce the incidence of hematological toxicities compared with six cycles of adjuvant chemotherapy in endometrial cancer patients with a high risk of recurrence.

The study enrolled 686 acute leukemia patients underwent allogeneic hematopoietic stem cell transplantation. The results indicated that obesity at pre-hematopoietic stem cell transplantation stage is correlated with poorer outcome.

We published chemotherapy-induced peripheral neuropathy guidelines in 2017 and conducted questionnaire survey in 2015 and 2019. The administration ratio of duloxetine increased in 2019 by the influence of the guidelines.

Based on the low incidence of adverse events and the high local control rate, proton beam therapy appears to be a feasible option for liver metastasis of gastric cancer.

Real-world safety and efficacy data from Japanese patients with EGFR T790M-positive NSCLC support the currently established benefit-risk assessment of osimertinib in this patient population.

Nivolumab demonstrated promising efficacy and reasonable safety for patients with post-operative recurrence of mesothelioma. Nivolumab can be considered a treatment option for patients with post-operative recurrence of mesothelioma.

We compared outcome 70 octogenarian patients to 205 septuagenarian patients with cN0 non-small-cell lung cancer. Our strategy for octogenarian patients, including omission of mediastinal lymph node dissection, was determined to be feasible.

This retrospective study showed that sarcopenia was significantly associated with cancer-specific survival in patients with metastatic hormone-sensitive prostate cancer, especially in younger patients.

In this Japanese post-marketing surveillance study, the safety and effectiveness profile of temsirolimus was similar to that in the multinational phase 3 study. No new safety signals were identified.

Combination treatment with temozolomide and etoposide showed beneficial therapeutic effects in two of nine patients with relapsed osteosarcoma, both were negative for O6-methylguanine-DNA methyltransferase protein expression.

A multicenter randomized phase III trial was initiated to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy over the standard treatment for locally recurrent rectal cancer.